Continuation of Drug Supply in Chinese Patients After CAMN107DBR01study Termination (MACS2226)

Novartis

Status

Conditions: Gastrointestinal Stromal Tumor

Treatments: Drug: Glivec

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT01613053

CAMN107DCN03

Details and patient eligibility

About

Continuation of drug supply in Chinese patients after CAMN107DBR01study termination.

Full description

Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained will enter the trial, all five patients will receive Glivec (8oomg per day) treatment until tumor progression [by RECIST guidelines, version 1.0], unacceptable toxicity, death or withdrawal of consent.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained.

Exclusion criteria

• N/A.